Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats.

MRP2 is an apical transporter expressed in hepatocytes and the epithelial cells of the small intestine and kidney proximal tubule. It extrudes organic anions, conjugated compounds, and some uncharged amphipaths. We studied the transport of an abundant food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in vitro, using an MRP2 transfected epithelial cell line (MDCK II) and intestinal explants from Wistar and MRP2-deficient TR(-) rats in Ussing chambers. In the experiments with the transfected cell line, we could demonstrate more than 3-fold higher transport from basolateral to apical than vice versa, whereas the transport in the parent cell line was equal in both directions. These results were confirmed in studies using isolated pieces of small intestine from Wistar and TR(-) rats in the Ussing chamber. Subsequent in vivo experiments demonstrated that after oral administration, absorption of PhIP was 2-fold higher in the TR(-) rat than in the Wistar rat. Consequently, PhIP tissue levels in several organs (liver, kidney, lung, and colon) were 1.7- to 4-fold higher 48 h after oral administration. MRP2 mediated transport of unchanged PhIP probably involves intracellular GSH, because GSH depletion by BSO-treatment in Wistar rats reduced intestinal secretion in the Ussing chamber to the same level as in TR(-) rats. In accordance, BSO treatment increased oral bioavailability in intact Wistar rats. This study shows for the first time that MRP2-mediated extrusion reduces oral bioavailability of a xenobiotic and protects against an abundant food-derived carcinogen.

[1]  M. Fromm,et al.  The effect of rifampin treatment on intestinal expression of human MRP transporters. , 2000, The American journal of pathology.

[2]  M. Vore,et al.  Expression and localization of multidrug resistant protein mrp2 in rat small intestine. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[5]  T. Walle,et al.  Transport of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: role of efflux pumps. , 1999, Carcinogenesis.

[6]  K. Turteltaub,et al.  In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). , 1999, Cancer letters.

[7]  T. Uchiumi,et al.  Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2) , 1999, FEBS letters.

[8]  R. Evers,et al.  Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. , 1999, The Biochemical journal.

[9]  D. Keppler,et al.  Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen , 1998, Archives of Toxicology.

[10]  S. Cole,et al.  Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. , 1998, Cancer research.

[11]  M. Jägerstad,et al.  Carcinogenic heterocyclic amines in model systems and cooked foods: a review on formation, occurrence and intake. , 1998, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[13]  J. Beijnen,et al.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.

[14]  D. Keppler,et al.  Induction of cMrp/cMoat gene expression by cisplatin, 2‐ acetylaminofluorene, or cycloheximide in rat hepatocytes , 1997, Hepatology.

[15]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[16]  D. Keppler,et al.  Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAJ) gene in liver , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  T. Massey,et al.  ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. , 1997, Molecular pharmacology.

[18]  M. Kool,et al.  A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin‐Johnson syndrome , 1997, Hepatology.

[19]  M. Debiec‐Rychter,et al.  Role of acetyltransferases in the metabolism and carcinogenicity of aromatic amines. , 1997, Mutation research.

[20]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Keppler,et al.  cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats* , 1996, The Journal of Biological Chemistry.

[22]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[23]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[24]  D. Meijer,et al.  Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. , 1995, Biochimica et biophysica acta.

[25]  J. Shaddock,et al.  Effect of glutathione depletion and inhibition of glucuronidation and sulfation on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism, PhIP-DNA adduct formation and unscheduled DNA synthesis in primary rat hepatocytes. , 1994, Carcinogenesis.

[26]  R. Minchin,et al.  Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. , 1994, Carcinogenesis.

[27]  P. Jansen,et al.  Preserved organic anion transport in mutant TR- rats with a hepatobiliary secretion defect. , 1993, The American journal of physiology.

[28]  N Ito,et al.  A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). , 1991, Carcinogenesis.

[29]  T. Sugimura,et al.  Fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rats. , 1991, Carcinogenesis.

[30]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Hatch,et al.  The isolation and identification of a new mutagen from fried ground beef: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). , 1986, Carcinogenesis.

[32]  W. Lamers,et al.  Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport , 1985, Hepatology.

[33]  J. Miners,et al.  The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. , 1984, Biochemical pharmacology.

[34]  D. Shrieve,et al.  Glutathione depletion in tissues after administration of buthionine sulphoximine. , 1984, International journal of radiation oncology, biology, physics.

[35]  F. Tietze.  Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.

[36]  Y. Sugiyama,et al.  Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[37]  G. Peters,et al.  Advances in Brief Antifolate Resistance Mediated by the Multidrug Resistance Proteins MRP 1 and MRP 21 , 2000 .

[38]  M. Vore,et al.  Expression and Localization of Multidrug Resistant Protein mrp 2 in Rat Small Intestine 1 , 2000 .

[39]  T. Uchiumi,et al.  Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. , 1999, American journal of human genetics.

[40]  T. Sugimura,et al.  DNA adduct formation, cell proliferation and aberrant crypt focus formation induced by PhIP in male and female rat colon with relevance to carcinogenesis. , 1996, Carcinogenesis.

[41]  H. Bartsch,et al.  Metabolic activation and DNA adduct detection of PhIP in dogs, rats, and humans in relation to urinary bladder and colon carcinogenesis. , 1995, Princess Takamatsu symposia.

[42]  J. Holme,et al.  Metabolism of the food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat and other rodents. , 1995, Princess Takamatsu symposia.